NCT00849524View on ClinicalTrials.gov

Study of Repeat Intranodal Injection of Memgen's Cancer Vaccine, Ad-ISF35, in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

PHASE2TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

July 31, 2009

Study Completion Date

July 31, 2014

Conditions
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Interventions
BIOLOGICAL

ISF35

Subjects participating in this study will be treated with multiple doses of Ad-ISF35 given via intranodal injection using a fixed dose of 3.3 x 10\^10 ISF35 viral particles. Intranodal injections will be administered every 2-4 weeks up to six total injections.

Trial Locations (1)

92093

University of California, San Diego Moores Cancer Center, La Jolla

Sponsors

Collaborators (1)

Memgen, LLC
All Listed Sponsors
collaborator

FDA Office of Orphan Products Development

FED

collaborator

Memgen, LLC

INDUSTRY

lead

Januario Castro, M.D.

OTHER

NCT00849524 - Study of Repeat Intranodal Injection of Memgen's Cancer Vaccine, Ad-ISF35, in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | Biotech Hunter | Biotech Hunter